Search CommunityWalk:


Novavax Inc

9920 Belward Campus Drive
Rockville, MD 20850, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

Novavax, Inc. is a biotechnology company creating vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The company's goal is to rapidly deliver a customized vaccine in the midst of a pandemic.

Novavax' research & development is focused on creating highly potent recombinant vaccines produced via cell culture. The company's proprietary technology platforms include: Virus-Like Particles and Novasome® paucilamellar vesicles. Its proprietary virus-like particle (VLP) technology builds a structure similar to a virus except for the genetic material required for viral replication. Once injected into the body, VLPs attach to cells and trigger an immune response sufficient enough to protect a person, if they are exposed to the virus.

Novavax targets its research efforts initially on various strains of viral influenza which include: H1N1 influenza referred to as swine flu, H5N1 pandemic influenza, often referred as bird flu, and seasonal influenza. It has created a VLP-based vaccine to protect against human immunodeficiency virus (HIV), the virus that causes AIDS.

Novavax' partners include: Acacia Research Corporatio, Biomedical Advanced Research and Development Authority, Cardinal Health Inc, Division of Microbiology and Infectious Diseases, Esprit Pharma, Inc, Ferndale Pharma Group, Inc, GlaxoSmithKline plc, IntelGenx Technologies Corp, King Pharmaceuticals, Inc, LG Life Sciences Ltd, National Institutes of Health, Organogenesis Inc, Pharmelle, Ranbaxy Laboratories Ltd, SmithKline Beecham Plc, Takeda America Holdings, Inc, United States Department of Health and Human Services, Vivalis, Wave Biotech LLC, Xcellerex, Inc and so on.